Top tips for prompting AI – A snapshot from The AI for Medical Affairs Course
Pharma pricing strategy in uncertain times
What good brand planning really looks like - Avoiding common pitfalls
6 Principles of pharmaceutical sales forecasting
Generating clinical evidence for HTA: challenges and solutions
How to build a future-proof AI adoption roadmap in pharma marketing
What is a QALY and how to calculate it? – By Prof. Dr. Lieven Annemans
Designing a Strategic KOL Plan for Success
Overview of the different KOL roles across the lifecycle of a product
9,5 steps to a successful Advisory Board Meeting – Do you actually need one?
Recorded Webinar: How to Set Prices When You Cannot Talk to Payers?
Understanding the interconnected landscape of payer types in the European healthcare environment
Omnichannel transformation: Where’s the industry at?
How to make sense of clinical evidence: Why statistical thinking matters
Why pharma product launches fail, according to Gary Johnson!
What Clinicians and Patients Need (and Want!) to Know About the Value for Money of New Health Innovations
Mastering pharma licensing negotiations: 6 Rules for a value-based structured approach
Overview of different valuation approaches in the life science industry
The clinical and non-clinical domains of Health Technology Assessment
Different types of pricing in pharma
Strategic foresight for global launch planning in pharma: Preparing for the market ahead
The in- & out-licensing processes at a glance
Thinking With Data
Checklist to assess pharma brand plan insights
Test your understanding of SWOTs
The importance of personas & segmentation for an omnichannel pharma launch
From Patient Flow & Journeys to CSFs – The best approach
Key Success Criteria for Real-World Evidence (RWE) Studies
Test your knowledge: Statistical thinking in medical affairs
The difference between Patient FLOW and Patient JOURNEY
Artificial Intelligence: How Effective is it for Pharma Pricing and Forecasting?
Do you know what a QALY is, and how to calculate it?
Preference scores from conjoint studies can be converted into useful market share estimates
Slide Snapshot: Overview of Internal Stakeholder KOL Needs
4 types of KOL mapping in pharma
Boosting Medical Affairs Impact: Ingredients for Success
Can AI Really Outperform Humans in Payer & Prescriber Interviews? The Surprising Evidence
From Patient Insights to Key Growth Drivers for Pharmaceuticals
The differences between multichannel and omnichannel in pharma
Do you know the difference between health economic evaluations and Health Technology Assessments?
What is a good Critical Success Factor (or: Strategic Imperative, Key Driver) for your brand in today’s VUCA pharma markets?
The 3 key elements to a successful omnichannel launch
What is an excellent launch in pharma?
Medical vs. pharmacy benefits in USA managed care
Medical Affairs: Rising to the Challenge
Can you forecast the relationship between your level of promotion and your sales?
The Pharma Brand Plan Quality Checklist
9,5 steps to a successful Advisory Board Meeting
Test your knowledge of pharma sales forecasting
Self-assessment test – Basics of Health Economics
The 2 dimensions of health economic evaluations
The anatomy of a medical plan – A guide for medical affairs professionals
7 Powerful negotiation tools used in Pharma Licensing Negotiations
The 10 possible criteria in HTA – 10 tips
The power of medical insights for success in pharma
Slide Snapshot: Payer Archetypes in Europe
The importance and structure of licensing term sheets in pharma/biotech
The core omnichannel components of a pharma launch
The case for a smarter early commercialisation strategy when launching a pharma brand
Tips for structuring a licensing deal between a biotech and a pharma company
3 Main challenges in pharma forecasting
Do you know the key drivers of price sensitivity for pharmaceuticals?
Omnichannel Launch Excellence: only one chance to get it right!
List of acronyms commonly used in RWE
Recorded Webinar: How to Avoid Common Mistakes with Conjoint Analysis in Pharma Market & Pricing Research
Preparing for the EU Joint Clinical Assessment HTA Process
Do you know the answer to this exercise on QALYs?
Commonly misused pricing terms in pharma
Omnichannel engagement: The key to successful pharmaceutical launches
Slide Snapshot: Deal types in pharma/biotech
Addressing Real-World Evidence (RWE) challenges in healthcare
How much is a payer willing to pay for a QALY gain? – By Prof. Dr. Lieven Annemans
The 4 payer types to be considered in optimising value pricing in pharma
The key to Market Access success is cross-functional collaboration
Checklist for evaluating an R&D product prior to out-licensing
How Business Development Optimally Contributes to the Pharmaceutical Value Chain
Agile Country-level Resource Optimisation Across a Pharma Portfolio & Across Brand Tactics
Unlock clarity in pharma pricing: Your go-to glossary for commonly misused terms
Do you have an effective Market Access planning process in place for new brands?
Do you know the 5 categories of payers and their respective roles and drivers?
Is biopharma ready for customer-centric omnichannel?
How to Optimise Portfolio Strategy in Pharma for Today AND Tomorrow
Top tips for setting KPIs for a country pharma launch
How to measure the ROI of your omnichannel campaigns in pharma
4 core MSL competencies: Training priorities for Medical Science Liaisons
Selecting the right Medical tactics based on Reach & Impact
Epi-based vs. sales-based forecasting in pharma: a false dichotomy?
Slide Snapshot: Fundamental Partnering Models in Pharma/Biotech
Exploring the layers of the pharmaceutical royalty stack
How Comparative RWE Can Help You with HTA and Payors When No RCT Evidence is Available
10 Practical guidelines for better health economic evaluations
Omnichannel Budget Planning for the New Normal
The many faces of a full HTA
Unlock the power of the Net Promoter Score (NPS) in pharma
Basics of Health Economics - Online Self-Study Programme: Preview
Recorded Webinar: Pricing and Forecasting Cell and Gene Therapies
The difference between ‘professional’ and ‘master’ level negotiation skills in pharma licensing
Cost-Effectiveness Analysis vs Budget Impact Analysis
Your EU5 Market Access acronyms / abbreviations list
6 Domains of Medical Affairs excellence: Unlocking the value of the Medical Affairs role
Challenges in Valuation: The In-Licensing Perspective
The value dossier and value story
Slide Snapshot: KPI Framework for Omnichannel in Pharma
The essence of global-to-local launch activation in pharma
Test your knowledge of pharma market access & payers in Europe
Are you ready for AI in pharma market access?
7 Key omnichannel marketing objectives and strategies to consider in pharma
What You Should Know About the QALY and About the Value of Health/QALY Gains with New Therapies
Integrative vs. distributive pharma licensing negotiation strategies
The 5 most useful sales forecasting techniques for pharmaceuticals
A holistic framework for evaluating pharmaceutical in-licensing opportunities
Slide Snapshot: Navigating the landscape of medical insight
Your US market access glossary
How AI Can Streamline Market Access and Reimbursement – From Dossier Writing to Strategic Decision-Making
Test your knowledge of pharmaceutical licensing
Driving Lifecycle Management Excellence Across the Full Product Lifecycle
Test your omnichannel knowledge & skills in pharma
Are you correctly forecasting the uptake of your brand(s)?
7 Negotiation skills you need to get the best possible pharma licensing deals
The role of RWE across the product lifecycle
Checklist to Assess Risk Factors & Drivers Impacting Valuation in Pharma/Biotech
Understanding the Knowledge Base in AI for pharma